

Seizures Therapeutic Pipeline Market Review, H2 2016

Global Seizures Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, August 30, 2016

/EINPresswire.com/ -- '[Seizures](#) - Pipeline Review, H2 2016', provides an overview of the Seizures pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects.



Complete report details @ <https://www.wiseguyreports.com/reports/619285-seizures-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain

competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Seizures
- The report reviews pipeline therapeutics for Seizures by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seizures therapeutics and enlists all their major and minor projects
- The report assesses Seizures therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seizures

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619285-seizures-pipeline-review-h2-2016>

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seizures
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619285-seizures-pipeline-review-h2-2016>

Key points in table of content

Table of Contents 2

List of Tables	5
List of Figures	6
Introduction	7
Global Markets Direct Report Coverage	7
Seizures Overview	8
Therapeutics Development	9
Pipeline Products for Seizures - Overview	9
Pipeline Products for Seizures - Comparative Analysis	10
Seizures - Therapeutics under Development by Companies	11
Seizures - Therapeutics under Investigation by Universities/Institutes	14
Seizures - Pipeline Products Glance	15
Late Stage Products	15
Clinical Stage Products	16
Early Stage Products	17
Unknown Stage Products	18
Seizures - Products under Development by Companies	19
Seizures - Products under Investigation by Universities/Institutes	23
Seizures - Companies Involved in Therapeutics Development	24
Adamas Pharmaceuticals, Inc.	24
Advicenne	25
Alexza Pharmaceuticals, Inc.	26
Biscayne Pharmaceuticals, Inc.	27
Catalyst Pharmaceuticals, Inc.	28
Eisai Co., Ltd.	29
GW Pharmaceuticals Plc	30
INSYS Therapeutics, Inc.	31
Lotus Pharmaceutical Co., Ltd.	32
Marinus Pharmaceuticals, Inc.	33
Neurelis, Inc.	34
Novartis AG	35
OPKO Health, Inc.	36
Pfizer Inc.	37
PTC Therapeutics, Inc.	38
Sage Therapeutics, Inc.	39
SciFluor Life Sciences, LLC	40
Shire Plc	41
SK Biopharmaceuticals Co., Ltd.	42
Suda Ltd	43
Turing Pharmaceuticals AG	44
UCB S.A.	45
Ultragenyx Pharmaceutical Inc.	46
Upsher-Smith Laboratories, Inc.	47
Xenon Pharmaceuticals Inc.	48

XERIS Pharmaceuticals, Inc. 49
Zogenix, Inc. 50
Zynerba Pharmaceuticals, Inc. 51
Seizures - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 57
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
ADS-4101 - Drug Profile 65
ADV-6208 - Drug Profile 66
ADV-6770 - Drug Profile 67
alprazolam - Drug Profile 68
AMPX-0079 - Drug Profile 70
ataluren - Drug Profile 71
BIS-001 - Drug Profile 79
brivaracetam - Drug Profile 80
cannabidiol - Drug Profile 84
cannabidiol - Drug Profile 90
CCG-63802 - Drug Profile 92
CHEC-9 - Drug Profile 93
clobazam - Drug Profile 94
CNSA-004 - Drug Profile 95
CPP-115 - Drug Profile 96
CUR-1916 - Drug Profile 100
diazepam - Drug Profile 101
diazepam - Drug Profile 103
everolimus - Drug Profile 104
fenfluramine hydrochloride - Drug Profile 115
fosphenytoin sodium - Drug Profile 118
ganaxolone - Drug Profile 119
lacosamide - Drug Profile 124
levetiracetam - Drug Profile 133
levetiracetam ER - Drug Profile 136
lorazepam - Drug Profile 137
LSPGR-1 - Drug Profile 138
magnesium valproate hydrate - Drug Profile 139
MB-003 - Drug Profile 140
midazolam hydrochloride - Drug Profile 141
midazolam hydrochloride - Drug Profile 144
midazolam hydrochloride - Drug Profile 145
midazolam hydrochloride - Drug Profile 146

Oligonucleotide for Dravet Syndrome - Drug Profile 147

perampanel - Drug Profile 148

pregabalin - Drug Profile 155

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619285

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/342362537>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.